Reactive, Lineage-by-Lineage Care Still Defines Anemia and Thrombocytopenia Management in ES-SCLC

Neutropenia draws the most attention in discussions of chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), but anemia and thrombocytopenia can be just as disruptive to a treatment course. Growth factor support, iron repletion, and transfusions are typically deployed reactively and one lineage at a time, an approach that can end up chasing toxicity rather than preventing it.

In a virtual Case-Based Roundtable event for oncologists in the Los Angeles area, Sudarsan Kollimuttathuillam, MD, an assistant clinical professor in the Department of Medical Oncology & Therapeutics Research at City of Hope, used a second case to walk participants through anemia and thrombocytopenia management in ES-SCLC, contrasting the reactive, single-lineage approach most attendees described with the multilineage protection offered by the CDK4/6 inhibitor trilaciclib (Cosela).

CASE SUMMARY

• A 63-year-old patient started receiving first-line carboplatin/etoposide/atezolizumab (Tecentriq) for ES-SCLC that presented with productive cough, chest pain, fatigue, anorexia, and recent 20-lb weight loss
• Past medical history: hypertension
• ECOG performance status: 1
• Prior to second cycle of therapy, he reports extreme fatigue and dizziness
• Workup and lab testing shows a decrease in hemoglobin (Hb) from 12.3 g/dL at baseline to 8 g/dL. No evidence of gastrointestinal bleed or hemolysis. Vitamin levels were checked for folate, B12, thyroid-stimulating hormone, and iron and were unremarkable. Reticulocyte hemoglobin content is within normal limits; reticulocytes are lower than expected for this level of anemia.
• Therapy delayed for 1 week, anemia improved to grade 1
• Second cycle administered with dose reduction (carboplatin)
• After second cycle, the Hb declines to 7.5 g/dL; red blood cell (RBC) transfusion administered

Kollimuttathuillam described how he screens for iron deficiency before chemotherapy starts, so a later drop can be attributed to treatment rather than worked up from scratch. Anthony Lam, MD, said he follows a similar rule: if a patient begins with a normal complete blood count and becomes anemic weeks into treatment, "I just blame it on the chemo" rather than repeating an extensive anemia workup. For anemia with a competing cause, several participants said they consider intravenous iron even though most iron products lack a cancer-specific indication; erythropoiesis-stimulating agents (ESAs) are approved for chemotherapy-induced anemia but carry warnings about tumor progression, and RBC transfusion, while effective, carries a roughly 10-fold greater risk of major morbidity than intravenous iron and takes 1 to 2 hours to arrange.¹

Prior to his fourth cycle, the patient developed grade 4 thrombocytopenia with uncontrollable nosebleeds, was hospitalized for transfusion, and held treatment for 3 weeks to recover to grade 1. Platelet transfusion remains the mainstay for chemotherapy-induced thrombocytopenia despite a short duration of benefit and an unpredictable increment, and is typically reserved for active bleeding, severe thrombocytopenia, or before invasive procedures; altering the chemotherapy dose and schedule remains the primary lever otherwise, even though reduced dose intensity has been linked to worse progression-free and overall survival in some studies.² Thrombopoietin receptor agonists came up as an option several participants said they rarely reach for in this setting.

Asked what they would do differently knowing how this case unfolded, 79% of polled attendees said they would give trilaciclib prior to cycle 1 and with each platinum/etoposide administration, vs 14% who favored upfront iron supplementation. Kollimuttathuillam illustrated how that would look in practice with a third patient, a 68-year-old man who received trilaciclib alongside all 4 cycles of etoposide/carboplatin/atezolizumab from cycle 1 onward and completed treatment without a single dose hold or delay attributable to CIM.³ Andrew Pham, MD, said the added infusion barely registers operationally: "I think the dose is more convenient than like it's like a premedication. It doesn't really add much to chair time or patient logistics." Robert Hsu, MD, noted that newer nonchemotherapy options, including tarlatamab (Imdelltra) and lurbinectedin (Zepzelca), are also reshaping the conversation, pointing to data supporting growth factor prophylaxis alongside lurbinectedin maintenance rather than waiting for cytopenia to appear.

By the close of the event, 71% of attendees said they were very likely or likely to change their overall approach to CIM prevention in ES-SCLC, evidence that the case-by-case, lineage-by-lineage pattern described throughout the discussion is starting to give way to earlier, broader prophylaxis.

REFERENCES

1. Soff G, Leader A, Al-Samkari H, et al. Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy. J Thromb Haemost. 2024 Jan;22(1):53-60. doi: 10.1016/j.jtha.2023.09.031.

2. Gilreath JA, Rodgers GM. How I treat cancer-associated anemia. Blood. 2020 Aug 13;136(7):801-813. doi: 10.1182/blood.2019004017.

3. COSELA (trilaciclib). Prescribing information. Pharmacosmos Therapeutics Inc; 2025. https://www.cosela.com/